Cytek Biosciences (CTKB) Stock Price, News & Analysis

Company Overview

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

Key Stats

• Today's Range: $4.09 to $4.20
• 50-Day Range: $3.10 to $4.17
• 52-Week Range: $2.37 to $7.63
• Volume: 735,856 shs
• Average Volume: 1.12 million shs
• Market Capitalization: $526.69 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.60
• Consensus Rating: Hold

Cytek Biosciences Stock Analysis - MarketRank™

Cytek Biosciences scored higher than 63% of companies evaluated by MarketBeat, and ranked 341st out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.1 / 5
• Analyst Rating: Hold

Consensus Rating

Cytek Biosciences has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 2 buy ratings, 2 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Cytek Biosciences has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Cytek Biosciences is -82.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cytek Biosciences is -82.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cytek Biosciences has a P/B Ratio of 1.35. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.43% of the float of Cytek Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Cytek Biosciences has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cytek Biosciences has recently decreased by 9.73%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cytek Biosciences does not currently pay a dividend.

Dividend Growth

Cytek Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.43% of the float of Cytek Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Cytek Biosciences has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cytek Biosciences has recently decreased by 9.73%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 1.37

News Sentiment

Cytek Biosciences has a news sentiment score of 1.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.12 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Cytek Biosciences this week, compared to 3 articles on an average week.

Search Interest

Only 2 people have searched for CTKB on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Cytek Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $194,600.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

10.33% of the stock of Cytek Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

69.46% of the stock of Cytek Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CTKB Stock Analysis - Frequently Asked Questions

How have CTKB shares performed this year?

Cytek Biosciences' stock was trading at $6.49 at the beginning of the year. Since then, CTKB stock has decreased by 36.2% and is now trading at $4.14.

How were Cytek Biosciences' earnings last quarter?

Cytek Biosciences, Inc. (NASDAQ:CTKB) announced its earnings results on Thursday, May, 8th. The company reported ($0.09) earnings per share for the quarter, missing analysts' consensus estimates of ($0.04) by $0.05. The firm earned $41.46 million during the quarter, compared to analysts' expectations of $43.18 million. Cytek Biosciences had a negative trailing twelve-month return on equity of 1.66% and a negative net margin of 3.27%.
Read the conference call transcript.

How will Cytek Biosciences' stock buyback program work?

Cytek Biosciences' board initiated a stock buyback plan on Monday, December 30th 2024, which authorizes the company to buy back $50,000,000 in shares, according to EventVestor. This means that the company could repurchase up to 5.9% of its shares through open market purchases. Shares buyback plans are often a sign that the company's board believes its shares are undervalued.

When did Cytek Biosciences IPO?

Cytek Biosciences (CTKB) raised $248 million in an IPO on Friday, July 23rd 2021. The company issued 14,564,635 shares at a price of $16.00-$18.00 per share.

Who are Cytek Biosciences' major shareholders?

Cytek Biosciences' top institutional investors include Brown Capital Management LLC (5.59%), Topline Capital Management LLC (4.11%), Geode Capital Management LLC (2.16%) and AQR Capital Management LLC (0.97%). Insiders that own company stock include Ming Yan, Wenbin Jiang, Patrik Jeanmonod, William D Mccombe and Jack Ball.
View institutional ownership trends.

How do I buy shares of Cytek Biosciences?

Shares of CTKB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Cytek Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cytek Biosciences investors own include American Water Works (AWK), Waste Connections (WCN), DiamondRock Hospitality (DRH), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), AU Optronics (AUOTY) and Humana (HUM).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 9/02/2025
• Next Earnings (Estimated): 11/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Measuring And Control Equipment
• Current Symbol: NASDAQ:CTKB
• CIK: 1831915
• Web: www.cytekdev.com
• Phone: 877-922-9835
• Fax: N/A
• Employees: 500
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Cytek Biosciences: $5.60
• High Price Target: $8.00
• Low Price Target: $3.00
• Potential Upside/Downside: +35.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.20
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.05)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$6.02 million
• Net Margins: -3.27%
• Pretax Margin: -3.86%
• Return on Equity: -1.66%
• Return on Assets: -1.30%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.22
• Quick Ratio: 4.55

Sales & Book Value

• Annual Sales: $200.45 million
• Price / Sales: 2.63
• Cash Flow: $0.03 per share
• Price / Cash Flow: 119.30
• Book Value: $3.07 per share
• Price / Book: 1.35

Miscellaneous

• Outstanding Shares: 127,220,000
• Free Float: 114,082,000
• Market Cap: $526.69 million
• Optionable: Optionable
• Beta: 1.36